Lyka Labs received product permission from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market Pregabalin Gel 8% in India. The gel is used for the treatment of neuropathic pain, marking a significant addition to the company’s product portfolio.
This new topical treatment, designed to relieve Diabetic Neuropathic Pain (DNP), represents a significant advancement in managing diabetes-related neuropathy in India, where diabetes cases have surged.
Clinical trials have demonstrated that the treatment is effective and well-tolerated, with fewer side effects compared to oral Pregabalin, marking a promising development for Lyka Labs.
Lyka Labs, a pharmaceutical company specializing in sterile and topical preparations, is actively advancing its research at its R&D Centre in Mumbai. The company is focused on developing a wide range of new formulations and drug delivery systems, particularly in the areas of Lyophilized Injectables and Topical Preparations.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
